Bradley Canino
Stock Analyst at Guggenheim
(4.51)
# 1,084
Out of 4,685 analysts
289
Total ratings
49%
Success rate
13.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Bradley Canino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CELC Celcuity | Rated: Buy | $165 → $175 | $95.08 | +84.06% | 16 | Aug 16, 2026 | |
| JANX Janux Therapeutics | Rated: Buy | $58 → $55 | $18.89 | +191.16% | 10 | Aug 6, 2026 | |
| ORIC ORIC Pharmaceuticals | Reiterated: Buy | $18 | $13.91 | +29.40% | 11 | Aug 3, 2026 | |
| KYMR Kymera Therapeutics | Reiterated: Buy | $125 → $135 | $125.55 | +7.53% | 21 | Jul 28, 2026 | |
| SMMT Summit Therapeutics | Rated: Buy | $40 → $38 | $14.23 | +167.04% | 16 | Jul 23, 2026 | |
| ANTX AN2 Therapeutics | Initiated Coverage: Buy | $9 | $5.53 | +62.75% | 1 | Jul 19, 2026 | |
| SNDX Syndax Pharmaceuticals | Maintained: Buy | $31 | $20.09 | +54.31% | 18 | Jul 14, 2026 | |
| DMRA Damora Therapeutics | Maintained: Buy | $40 | $30.39 | +31.62% | 5 | Jun 15, 2026 | |
| OLMA Olema Pharmaceuticals | Maintained: Buy | $38 → $35 | $10.85 | +222.58% | 5 | Jun 1, 2026 | |
| BCAX Bicara Therapeutics | Maintained: Buy | $42 | $24.73 | +69.83% | 2 | May 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $22 → $26 | $19.46 | +33.61% | 18 | May 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 | $18.02 | +94.23% | 3 | Apr 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $54 | $26.22 | +105.95% | 1 | Apr 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $22.85 | +31.29% | 7 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $90 | $78.42 | +14.77% | 3 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 → $7 | $4.24 | +65.09% | 20 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $2.27 | - | 17 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $13.06 | - | 21 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $10 → $5 | $3.34 | +49.70% | 5 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $9 | $3.89 | n/a | 23 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $3 → $1.5 | $1.98 | n/a | 20 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $63 → $51 | $9.32 | n/a | 25 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.0001 | n/a | 13 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $37 | $4.04 | n/a | 1 | Apr 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $65 | $60.04 | n/a | 1 | Apr 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $15 | $18.40 | n/a | 1 | Apr 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $68 | $3.12 | n/a | 1 | Apr 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $30 | $5.43 | n/a | 1 | Apr 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $30 | $56.10 | n/a | 1 | Mar 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $55 | $29.31 | n/a | 1 | Mar 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $38 | $35.42 | n/a | 1 | Jul 8, 2020 |
Celcuity
Aug 16, 2026
Rated: Buy
Price Target: $165 → $175
Current: $95.08
Upside: +84.06%
Janux Therapeutics
Aug 6, 2026
Rated: Buy
Price Target: $58 → $55
Current: $18.89
Upside: +191.16%
ORIC Pharmaceuticals
Aug 3, 2026
Reiterated: Buy
Price Target: $18
Current: $13.91
Upside: +29.40%
Kymera Therapeutics
Jul 28, 2026
Reiterated: Buy
Price Target: $125 → $135
Current: $125.55
Upside: +7.53%
Summit Therapeutics
Jul 23, 2026
Rated: Buy
Price Target: $40 → $38
Current: $14.23
Upside: +167.04%
AN2 Therapeutics
Jul 19, 2026
Initiated Coverage: Buy
Price Target: $9
Current: $5.53
Upside: +62.75%
Syndax Pharmaceuticals
Jul 14, 2026
Maintained: Buy
Price Target: $31
Current: $20.09
Upside: +54.31%
Damora Therapeutics
Jun 15, 2026
Maintained: Buy
Price Target: $40
Current: $30.39
Upside: +31.62%
Olema Pharmaceuticals
Jun 1, 2026
Maintained: Buy
Price Target: $38 → $35
Current: $10.85
Upside: +222.58%
Bicara Therapeutics
May 26, 2026
Maintained: Buy
Price Target: $42
Current: $24.73
Upside: +69.83%
May 25, 2026
Maintained: Buy
Price Target: $22 → $26
Current: $19.46
Upside: +33.61%
Apr 29, 2026
Maintained: Buy
Price Target: $35
Current: $18.02
Upside: +94.23%
Apr 15, 2026
Initiated Coverage: Buy
Price Target: $54
Current: $26.22
Upside: +105.95%
Mar 10, 2026
Reiterated: Buy
Price Target: $30
Current: $22.85
Upside: +31.29%
Feb 27, 2026
Reiterated: Buy
Price Target: $90
Current: $78.42
Upside: +14.77%
Feb 26, 2026
Reiterated: Buy
Price Target: $8 → $7
Current: $4.24
Upside: +65.09%
Dec 3, 2025
Downgraded: Hold
Price Target: n/a
Current: $2.27
Upside: -
Sep 3, 2025
Initiated Coverage: Hold
Price Target: n/a
Current: $13.06
Upside: -
Sep 3, 2025
Initiated Coverage: Buy
Price Target: $10 → $5
Current: $3.34
Upside: +49.70%
Mar 27, 2025
Maintained: Buy
Price Target: $9
Current: $3.89
Upside: n/a
Mar 7, 2025
Maintained: Hold
Price Target: $3 → $1.5
Current: $1.98
Upside: n/a
Feb 12, 2025
Maintained: Buy
Price Target: $63 → $51
Current: $9.32
Upside: n/a
Jan 9, 2025
Rated: Hold
Price Target: n/a
Current: $0.0001
Upside: n/a
Apr 26, 2021
Initiated Coverage: Buy
Price Target: $37
Current: $4.04
Upside: n/a
Apr 26, 2021
Initiated Coverage: Buy
Price Target: $65
Current: $60.04
Upside: n/a
Apr 26, 2021
Initiated Coverage: Buy
Price Target: $15
Current: $18.40
Upside: n/a
Apr 26, 2021
Initiated Coverage: Buy
Price Target: $68
Current: $3.12
Upside: n/a
Apr 26, 2021
Initiated Coverage: Buy
Price Target: $30
Current: $5.43
Upside: n/a
Mar 30, 2021
Initiated Coverage: Buy
Price Target: $30
Current: $56.10
Upside: n/a
Mar 30, 2021
Initiated Coverage: Buy
Price Target: $55
Current: $29.31
Upside: n/a
Jul 8, 2020
Initiated Coverage: Buy
Price Target: $38
Current: $35.42
Upside: n/a